v3.26.1
Segments - Schedule of Revenues by Major Products and Activities (Detail) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Product Information [Line Items]      
Revenues $ 17,258 $ 16,544 $ 15,846
United States [Member]      
Product Information [Line Items]      
Revenues 7,690 6,498 6,154
Europe [Member]      
Product Information [Line Items]      
Revenues 5,040 5,103 4,837
International Markets [Member]      
Product Information [Line Items]      
Revenues 2,162 2,463 2,351
Generic products (including OTC and biosimilars) [Member] | United States [Member]      
Product Information [Line Items]      
Revenues 3,657 3,599 3,138
Generic products (including OTC and biosimilars) [Member] | Europe [Member]      
Product Information [Line Items]      
Revenues 4,044 3,926 3,664
Generic products (including OTC and biosimilars) [Member] | International Markets [Member]      
Product Information [Line Items]      
Revenues 1,721 1,937 1,932
AJOVY [Member] | United States [Member]      
Product Information [Line Items]      
Revenues 295 207 211
AJOVY [Member] | Europe [Member]      
Product Information [Line Items]      
Revenues 270 216 160
AJOVY [Member] | International Markets [Member]      
Product Information [Line Items]      
Revenues 108 84 63
AUSTEDO [Member] | United States [Member]      
Product Information [Line Items]      
Revenues 2,217 1,642 1,225
AUSTEDO [Member] | International Markets [Member]      
Product Information [Line Items]      
Revenues 43 46 15
BENDEKA and TREANDA [Member] | United States [Member]      
Product Information [Line Items]      
Revenues 147 168 237
COPAXONE [Member] | United States [Member]      
Product Information [Line Items]      
Revenues 255 242 297
COPAXONE [Member] | Europe [Member]      
Product Information [Line Items]      
Revenues 181 213 231
COPAXONE [Member] | International Markets [Member]      
Product Information [Line Items]      
Revenues 32 48 63
UZEDY [Member] | United States [Member]      
Product Information [Line Items]      
Revenues 191 117 23
Respiratory Product [Member] | Europe [Member]      
Product Information [Line Items]      
Revenues 227 244 265
Other [Member] | United States [Member]      
Product Information [Line Items]      
Revenues [1] 929 523 1,024
Other [Member] | Europe [Member]      
Product Information [Line Items]      
Revenues [2] 319 504 516
Other [Member] | International Markets [Member]      
Product Information [Line Items]      
Revenues [3] $ 259 $ 349 $ 278
[1] Other revenues in 2025 were mainly comprised of milestone payments of $500 million received in the fourth quarter of 2025, in connection with the initiation of Phase 3 studies for duvakitug (anti-TL1A) (see note 2 to our consolidated financial statements). Other revenues in 2024 include the sale of certain product rights. Other revenues in 2023 were mainly comprised of a $500 million upfront payment received in the fourth quarter of 2023, in connection with the collaboration on Teva’s duvakitug (anti-TL1A) asset.
[2] Other revenues in 2025, 2024 and 2023 include the sale of certain product rights.
[3] Other revenues in 2025 and 2024 include the sale of certain product rights.